Impact of Initial Management on Disease Evolution in Vogt-Koyanagi-Harada Syndrome: A Retrospective Cohort of 50 Patients

PurposeThe study aims to determine the impact of initial management in Vogt-Koyanagi-Harada syndrome (VKHS).MethodsPatients diagnosed with a VKHS between January 2001 and December 2020 in two French tertiary centers were included in a retrospective study.ResultsFifty patients were included with a median duration of follow-up of 29.8 months. All patients received oral prednisone after methylprednisolone in all but four of them. Five patients received at least one associated immunosuppressive therapy (IST) within the first 6 months and 26 patients received IST during the entire follow-up period. Twenty-eight patients presented at least one relapse at a median of 5.4 months from diagnosis. Multivariate analyses demonstrated a significant association between relapse and delayed treatment (>26 days) (HR = 3.69, CI95% 1.30-10.47, p = .01), whereas no association was observed between relapse and the number of corticosteroid pulses at initial management.ConclusionAn early corticosteroid treatment within the first 26 days of symptoms decreased the relapse rate.